- Home
- EPAM vs RVTY Comparison
EPAM vs RVTY Comparison
Compare EPAM & RVTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EPAM | RVTY |
|---|---|---|
| Founded | 1993 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 11.7B |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | EPAM | RVTY |
|---|---|---|
| Price | $210.88 | $103.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 14 |
| Target Price | ★ $215.64 | $113.46 |
| AVG Volume (30 Days) | 697.2K | ★ 1.1M |
| Earning Date | 02-19-2026 | 01-30-2026 |
| Dividend Yield | N/A | ★ 0.27% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.55 | 1.99 |
| Revenue | ★ $5,297,859,000.00 | $2,813,367,000.00 |
| Revenue This Year | $17.39 | $5.33 |
| Revenue Next Year | $7.03 | $3.03 |
| P/E Ratio | ★ $32.35 | $52.44 |
| Revenue Growth | ★ 14.26 | 3.37 |
| 52 Week Low | $138.15 | $81.36 |
| 52 Week High | $269.00 | $128.29 |
Technical Indicators
Market Signals| Indicator | EPAM | RVTY |
|---|---|---|
| Relative Strength Index (RSI) | 56.10 | 60.55 |
| Support Level | $199.80 | $100.98 |
| Resistance Level | $221.99 | $106.39 |
| Average True Range (ATR) | 5.91 | 2.49 |
| MACD | -0.71 | 0.62 |
| Stochastic Oscillator | 49.94 | 72.87 |
Price Performance
Historical ComparisonAbout EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm with a focus on platform engineering, software development, and consulting services. The company used to host large engineer bases in Ukraine, Belarus, and Russia, but it now delivers from various locations across different continents. EPAM's largest market is North America, which represents approximately 60% of revenue.
About RVTY Revvity Inc.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.